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Session Plan
 Overview of HAND
 Approaches to assessment &  screening
 Practice test administration
 Discussion, Q&A
Definitions
 Very confused, until recently  e.g.,
 ARC
 AIDS Dementia Complex
 HIV/AIDS Encephalopathy
 HIV/AIDS Dementia
 HIV Minor Cognitive Motor Disorder
 now some agreement on…
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Definitions1
HIV-Associated Neurocognitive Disorder
 HAND,  is the general term covering:
 Asymptomatic Neurocognitive Impairment 
 H-ANI – mild
 HIV-associated Mild Neurocognitive Disorder
 H-MND – moderate
 HIV-associated Dementia
 H-AD – severe
Definitions
 Asymptomatic Neurocognitive Impairment 
 mild cognitive impairment in 2 or more functions
 no impairment in ADLs
 Mild Neurocognitive Disorder
 mild cognitive impairment in 2 or more functions
 mild impairments in ADLs
 HIV-associated Dementia
 marked cognitive impairment in 2+ functions
 marked impairments in ADLs
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Definitions
 Mild cognitive impairment
 = more than 1 SD below mean expected
 Marked cognitive impairment
 = more than 2 SD below mean expected
 Impairment in ADLs
 reported by self, informant, or observed
 Not attributable to delirium or other causes
Prevalence2
 Asymptomatic Neurocognitive Impairment 
 33%
 Mild Neurocognitive Disorder
 12%
 HIV-associated Dementia
 2%
1555 HIV+ clients receiving CART in 6 US research clinics
NHIVNA Study Day Programme 2012
Dr Matthew Jones-Chesters 5
HAND & CART
CART has …
 Reduced severity of HAND
 Reduced incidence of HIV dementia
 Reduced progression from mild to marked
 Increased prevalence of milder HAND
 More ‘static’ profile, with fluctuation
 Increased interaction with aging
Outcomes
 Reversal
 evidence of restoration of function on initiation of 
CART in naïve patients
 evidence of reversal/inhibition of decline in CART 
adjusted to include highly CNS-penetration
 Statis
 asymptomatic-untreated and CART-treated may 
remain static – not a ‘degenerative’ illness
 Progression
 Untreated, symptomatic and co-morbid presentations 
may lead to decline
NHIVNA Study Day Programme 2012
Dr Matthew Jones-Chesters 6
Neuropsychological Deficits3
Triad of Impairments
 Cognitive
 Motor
 Personality
Suggestive of
 Subcortical dementia, or
 Fronto-striatal syndrome
≈ Parkinson’s disease, PSP, vascular dementia
(and not Alzheimer’s-type)
Profile of Deficits
1. Cognitive
 information processing speed
 psychomotor speed & coordination
 attention and concentration
 executive function (switching between tasks)
 learning and memory
2. Motor
 Gait, incoordination, tone, tremor
3. Mood & Behaviour
 apathy, depression;  impulsivity, agitation
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Emergence of Deficits
 Asymptomatic Neurocognitive Impairment 
 mild cognitive decline (2 or more areas)
 Mild Neurocognitive Disorder
 mild cognitive impairment (2 or more areas)
 + mild-moderate motor dysfunction
 HIV-associated Dementia
 marked cognitive impairment
 + moderate-severe motor dysfunction
 + mood and behaviour disturbance
Typical HAD Profile
Cognitive
 Impaired attention and processing speed
 Impaired new learning and memory
 Impaired verbal abstraction and visuospatial skills
Motor
 Slow motor speed, poor manual dexterity
 Neurological : abnormal gait, limb incoordination
Personality
 apathy, inertia, irritability, emotional lability,
 impaired judgment and social skills, disinhibition.
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Neuronal Dysfunction4
MRI/fMRI and PET suggest
 decreased metabolism in thalamus
 decreased metabolism in basal ganglia 
 diffuse non-enhancing white-matter 
hyperintensity
 cerebral atrophy and
 ventricular enlargement in later stages
Neuronal Dysfunction
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Aetiology5
 Primary Viral Syndromes
 Secondary Neurological Sequelae
Primary  Presentations
 CNS disorder
 Other neuropathies
 Vacuolar myelopathy
 Peripheral neuropathies
 Polymyositis
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Neuronal  Processes
 Neuro-invasion? Doubtful?
 HIV may enter CNS by transcytosis of 
endothelial cells
 replicates in endothelial cells and infects monocytes, 
microglia, oligodendrocytes. astrocytes, 
macrophages.
 these release chemokines, pro-inflammatory 
cytokines, nitrous oxide or other neurotoxins
 also CNS damage by immune response
Secondary  Presentations
 Opportunistic viral illnesses
 Nonviral infections
 Neoplasms
 Cerebrovascular
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Opportunistic viral illnesses 
 Cytomegalovirus (CMV)
 Herpes simplex virus Types 1 and 2 
 Varicella zoster virus
 Papovavirus PML
 progressive multi-focal leukoencephalopathy
 Adenovirus Type 2
Nonviral infections
 Toxoplasma gondii
 Cryptococcus 
neoformans
 Candida albicans
 Aspergillus fumigatus
 Coccidioides immitis
 Mucormycosis
 Rhizopus sp.
 Acremonium 
alabamensis
 Histoplasma 
capsulatum
 Mycobacterium 
hominis tuberculosis
 Mycobacterium 
avium-intracellulare
 Listeria 
monocytogenes
 Nocardia asteroides
 Streptococcus 
pneumonia
 Hemophilus influenza
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Neoplasm
 Primary CNS lymphoma
 Metastatic systemic lymphoma
 Metastatic Kaposi's sarcoma
Cerebro-vascular
 Ischaemic-haemorrhagic infarction
 Haemorrhage
 Vasculitis
Adherence
 Interaction with CART Adherence
 poor adherence  → poor suppression
 poor suppression → cognitive decline
 cognitive decline → poor adherence
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Assessment: Rationale
 Detect and limit disease progression
 HAND is associated with ↑ mortality
 Adjust CART regimen
 Prompt closer/assertive monitoring
 Detect other pathologies
 Treat other pathologies
 Assert and support adherence
Assessment: Rationale
 Provide support
 Provide education & information
 Refer for cognitive rehabilitation
 Refer for functional support
 Refer for psychological support
 Preserve independence
 Protect from abuse
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Assessment : Strategy
 How to detect and measure …?
 cognitive impairment
 neurological disorder
 impairment in ADLs
Assessment : Strategy
 Cognitive impairment
 Refer for neuropsychological assessment
 screening cognitive assessment
 Neurological disorder
 clinic review
 Impairment in ADLs
 patient report;  informant report
 IADLS instruments
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Cognitive Domains
 Orientation (to exclude delirium)
 Processing Speed
 Motor coordination
 Attention
 Execution
 Memory
 Language
 Visual-perceptual function
Screening  Instruments
 Brief HIV-specific
 HIV Dementia Scale (HDS)
 International HIV Dementia Scale (IHDS)
 Generic Mental Status
 Mini Mental State Examination (MMSE)
 Montreal Cognitive Assessment (MoCA)
 Computerised
 CogState
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HIV Dementia Scale (HDS)6
1.  Memory Registration:
Give four words to recall (dog, hat, green, peach) – one second to say 
each. Ask the patient to repeat all 4 after you have said them.
2. Anti-saccadic Attention
With hands up at patient's shoulder-width and eye-height, ask patient to 
look at nose, and then look at hand if any fingers move.  Examiner 
moves index finger of one hand, checks response, and repeats 
until patient is familiar with task.  Then examiner changes 
instruction, asking patient (when fingers move) to look at the fingers 
of the other (non-moving) hand: a measure of inhibition.
Perform 20 trials: An error is when the patient looks at moving finger.
<3 errors = 4; 4 errors = 3; 5 errors = 2; 6 errors = 1; >6 errors = 0
HIV Dementia Scale (HDS)
3. Psychomotor Speed
Ask patient to write the alphabet in upper case letters horizontally 
across the page and record time in seconds.
<21 s = 6;     21.1 to 24 s = 5;     24.1 to 27 s = 4;
27.1 to 30 s = 3; 30.1 to 33 s = 2;   33.1 to 36 s = 1;   >36 s = 0
4. Word Recall
SAY:  “Now, tell me those four words I asked you to repeat to me 
a few minutes ago.” I point per item correct.
5. Construction
Present  wire cube design, ask patient to copy
and record time to completion.
<25 sec = 2; 25 to 35 sec = 1; >35 sec = 0
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HIV Dementia Scale (HDS)
 5 minutes to administer, simple tasks
 Score a total composite out of 16
 Good for neurology and speed
 Fair for attention, memory and visual
 No screen for delirium
 No tests of frontal-executive function
 Insensitive to mild impairments
 Sensitivity and specificity fair for HAD
International  HDS7
1.  Memory Registration:
Give four words to recall (dog, hat, bean, red) – one second 
to say each. Ask the patient to repeat all 4 after you 
have said them.
2.  Motor Speed:
Ask patient to tap the first two fingers of the non-dominant 
hand as widely and as quickly as possible. Record for 
15 seconds and count taps achieved
4 = 15 = 4;  3 = 11-14;  2 = 7-10;   1 = 3-6;  0 = 0-2 in 5s.
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International  HDS
3. Psychomotor Speed:
SAY: “Look carefully at what I am doing.” With left hand, 
perform 3 fist-chop-slap cycles.  Demonstrate and have 
patient perform twice for practice.  SAY: “Now, with your 
(non-dominant) hand, do the same as me, first with me.”
Perform cycles with client, until sequence is learned, then 
SAY:  “Good, now keep going, as quickly as you can.”
Count cycles achieved in 10 seconds:
Score 4 = 4 seq;  3 = 3 seq;  2 = 2 seq;  1 = 1 seq;  0 = unable 
4.  Memory-Recall
Ask the patient to recall the four words. For words not recalled, 
prompt with a semantic clue as follows: animal (dog); piece 
of clothing (hat); vegetable (bean); colour (red). 
1 point for each spontaneous recall;  0.5 for prompted answers
International  HDS
 <5 minutes to administer, simple tasks
 Score a total composite out of 12
 Fair for neurology and speed
 Fair for attention and memory
 No screen for delirium
 No tests of frontal-executive function
 Very insensitive to mild impairments
 Sensitivity and specificity fair for HAD
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MMSE8
MMSE
CLOSE YOUR EYES
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MMSE
 10 minutes to administer, very familiar
 Score a total composite out of 30
 10/30 based on Orientation
 good for delirium, though not specific to HAND
 No test of frontal-executive function
 No test of processing speed
 No test of gait or neurological function
 Poor sensitivity and specificity for HAND
MoCA9
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MoCA
MoCA
NHIVNA Study Day Programme 2012
Dr Matthew Jones-Chesters 22
MoCA
 15 minutes to administer, needs practice
 Score composite (/30), but also at task level
 Good on attention and executive function
 Includes orientation
 Includes learning & memory
 Includes language and visual-perception
 No test of processing speed
 Sensitivity and specificity for HAND not known
CogState10
 Computer-based test, operated over internet
 Self-administered, automatically scored
 15-20 minutes to complete
 Subtests ‘build’ on each other
 Instructions given by demonstration & feedback
 Assesses both speed (RT) and accuracy
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CogState
Subtests
 Simple reaction time
 Choice reaction time
 Complex reaction time
 Continuous performance (monitoring)
 One-back working memory
 Matching
 Incidental learning
 Associate learning
CogState: complex choice RT
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CogState: monitoring
CogState: matching
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CogState
 20 minutes to administer
 Scores at sub-task level
 Good on attention and processing speed
 Includes learning & memory
 Minimal for executive function
 No test of orientation
 No tests of language or visual-perception
 Sensitivity and specificity for HAND fair
Interpretation
 Premorbid Ability
 More able patients do better:
 good scores mask emerging problems 
 Education
 More educated patients do better:
 good scores mask emerging problems
 Language
 EAL patients obtain lower scores:
 interpret low scores with caution
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Test Evaluation 
 No one set covers all needed domains
 HIV-specific sets
 address key deficits
 but are insensitive
 Generic sets
 address  cognition broadly
 but miss key areas of HIV presentation
 Solution:  combine
Summary 
 Cognitive impairments common in HIV
 associated with ↓adherence, ↑mortality
 Assess IADLS
 assess cognition
 use tests in combination
 interpret with care
 Refer when in doubt
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